GSK plc

Approval AI-extracted

Exdensur

severe asthma with an eosinophilic phenotype and nasal polyps

Resolved

69days ago

Approval decision · Apr 29, 2026

What's at stake A final FDA approval decision on Exdensur for severe asthma with an eosinophilic phenotype and nasal polyps is expected Apr 29, 2026.

Primary source · SEC 6-K verified 12h ago

“New product approvals for: Exdensur (EU & China for severe asthma with an eosinophilic phenotype and nasal polyps);”